Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

BACKGROUND: Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20–40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jessurun, Charissa A. C., Vos, Julien A. M., Limpens, Jacqueline, Luiten, Rosalie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625582/
https://www.ncbi.nlm.nih.gov/pubmed/29034210
http://dx.doi.org/10.3389/fonc.2017.00233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625582/
https://www.ncbi.nlm.nih.gov/pubmed/29034210
http://dx.doi.org/10.3389/fonc.2017.00233

Ejemplares similares